Scisparc Ltd.

Biotechnology • Healthcare • Tel Aviv, Israel • SPRC (NCM)

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. It also sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110, palmitoylethanolamide oral tablets and CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv, Israel.

972 7 334 47180 Tower A, Israel

Stock Performance (90 Days)

Data through Dec 29, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

SciSparc (Nasdaq: SPRC) NeuroThera signs term sheet for 55% quantum data stake - Stock Titan

Stock Titan • Dec 2

SciSparc stock tumbles after announcing MUSE system acquisition plans - Investing.com

Investing.com • Dec 1

SciSparc Ltd.'s Majority-Owned NeuroThera Labs Receives Patent for Opioid-N-acylethanolamine Combination to Enhance Pain Management - Quiver Quantitative

Quiver Quantitative • Dec 30

SciSparc Stock Soars Pre-Market After Snapping Up Patents For Next-Gen Endoscopy Tech - Stocktwits

Stocktwits • Nov 26

SciSparc Stocks Surge 50% In Pre-Market After N2OFF Approves MitoCareX Acquisition - Nasdaq

Nasdaq • Sep 30

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has SciSparc Ltd. had layoffs?

No layoff events have been recorded for SciSparc Ltd. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does SciSparc Ltd. have?

SciSparc Ltd. has approximately 2 employees.

What industry is SciSparc Ltd. in?

SciSparc Ltd. operates in the Biotechnology industry, within the Healthcare sector.

Is SciSparc Ltd. a publicly traded company?

Yes, SciSparc Ltd. is publicly traded under the ticker symbol SPRC on the NCM. The company has a market capitalization of approximately $0.00 billion.

Where is SciSparc Ltd. headquartered?

SciSparc Ltd. is headquartered in Tel Aviv, Israel at Tower A, Israel.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.